about
Expression of membrane-type 5 matrix metalloproteinase in human endometrium and endometriosisStructure, expression and chromosomal mapping of TKT from man and mouse: a new subclass of receptor tyrosine kinases with a factor VIII-like domainTyrosine-614, the major autophosphorylation site of the receptor tyrosine kinase HEK2, functions as multi-docking site for SH2-domain mediated interactionsNef proteins of distinct HIV-1 or -2 isolates differ in their binding properties for HCK: isolation of a novel Nef binding factor with characteristics of an adaptor protein.Characterization of WNT7A expression in human endometrium and endometriotic lesions.Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer.Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer.A clinically relevant gene signature in triple negative and basal-like breast cancerControl of dataset bias in combined Affymetrix cohorts of triple negative breast cancerBreast Cancer Proteomics - Differences in Protein Expression between Estrogen Receptor-Positive and -Negative Tumors Identified by Tandem Mass Tag TechnologyThe role of genetic breast cancer susceptibility variants as prognostic factors.T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters.High-throughput gene expression and mutation profiling: current methods and future perspectives.Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersRecommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers.Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.CD73 is associated with poor prognosis in high-grade serous ovarian cancer.PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition.The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and facilitates breast cancer metastasis.Fascin-1 expression as stratification marker in borderline epithelial tumours of the ovary.The prognostic impact of age in different molecular subtypes of breast cancer.OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancerAcid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer.Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.Clinical relevance of the putative stem cell marker p63 in breast cancer.Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer.Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer.Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.
P50
Q28254260-5BAF4253-5268-4D1E-A287-A2E8C8CDE80DQ28256857-698716E4-3649-4F26-87F7-6218A754B8FDQ28277260-16239C36-EDF4-46EA-BE4F-95588831A980Q30176132-07C1A8C7-1ECF-495B-8844-7D0942E41D5AQ33288673-E3FC92C5-F834-4B28-A431-69BD77BED127Q33448620-AD16522E-1A0B-4811-9683-9C5C462B1787Q33519812-5B7868E1-E886-438A-89DF-23E78E7CC5D9Q34119025-B7BC09A1-1DA0-497A-ACC2-2ABF28C8E95CQ34576614-07D4C0CA-A35E-4C81-821A-AFA0CFE533BFQ35161221-23A249DC-6288-4B2E-ACF0-0EB3F80209BFQ35683578-42BABA24-B102-48D5-AE94-C82422BFFB4AQ35951787-F8064967-30DC-4C94-A6F6-967FC7C88065Q35976097-42E6EDD6-3615-4F1A-AC32-891816A29AF9Q36142060-954A9EA4-6F43-40D9-9103-AF349A61E396Q37208738-FC4DD37D-CF00-4EF2-B0ED-4F1A6819EB52Q37287502-4D24C5E0-1D95-44B1-88C0-E7F833789FE5Q37573642-FF24B244-914A-4813-943D-3081027AD822Q37690351-234F1BEA-746E-4C2E-933C-F5F12B8AA42BQ37970938-4B4D79AE-2406-4917-AE9C-54A661A93ED2Q38290413-22C5C320-F6F8-4D4F-ACFC-0B810A72A43CQ38603188-D7ACCD30-3ABC-4D6B-A081-9856CD716212Q38657423-EE1AA44D-C219-4435-887A-DCC1048306B1Q38827746-531238B3-FA18-46C6-8A3B-DD649782A91EQ38835904-E2064A14-AF0F-4C75-9BF9-C80B93B1B85EQ38913313-C2C52011-636B-49E1-A68E-F2FABB1F17E1Q38960668-605CEB28-8714-4C96-8E10-AF1787FB4610Q40547169-9FD90452-9188-4EE9-BA32-8A456C2CBD71Q40714796-420A8F94-C370-4F3C-9889-2D814985C495Q41135180-50548BEF-AF75-402D-92DD-C8FAA578C1AEQ41135883-4A52C410-B6F1-4F30-9875-D3F085B13E8DQ41479168-9E4BFE19-8A5F-4077-B2BA-7517E75C5741Q42462630-2430314E-3C32-4B79-893A-71F558711D56Q42491260-08563983-A8EE-4CC8-8BF7-B465E116D81FQ42517986-78EDE459-AD55-49E0-8439-2EA80F2A5C68Q42638803-D6921499-14E1-47FD-8A8B-E04B48FC8C5BQ43244413-EB832D4B-3C7D-4030-86F4-81F6BAB5DF97Q43549877-E41F5FFB-0FF2-451D-B757-15E954BE5DDFQ43984955-B0E48389-7C98-4828-82DA-605E17E80D50Q44258071-6357C5B5-736F-4A41-AA73-87563AD8373CQ44384187-F5685279-FBAD-496B-BE48-C954296644AB
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Karn
@ast
Thomas Karn
@en
Thomas Karn
@es
Thomas Karn
@nl
Thomas Karn
@sl
type
label
Thomas Karn
@ast
Thomas Karn
@en
Thomas Karn
@es
Thomas Karn
@nl
Thomas Karn
@sl
prefLabel
Thomas Karn
@ast
Thomas Karn
@en
Thomas Karn
@es
Thomas Karn
@nl
Thomas Karn
@sl
P214
P1053
C-7452-2013
P106
P21
P214
P31
P3829
P496
0000-0002-3264-6573
P734
P735
P7859
viaf-74642426